StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Doxycyclin

4-(Dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboximidic acid

HCID 54671203
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
564-25-0
Standard-SMILES
C[C@H]1c2cccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
InChIKey
SGKRLCUYIXIAHR-AKNGSSGZSA-N
Summenformel
C22H24N2O8
Durchschnittliche Molmasse
444,4 g/mol
Monoisotopische Masse
444,15326573

Überblick

Doxycycline (internal use) can cause developmental toxicity according to state or federal government labeling requirements.

Namen und Bezeichner

Bevorzugter Name
4-(Dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboximidic acid
IUPAC
(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
Lokaler Name
Doxycyclin
Englischer Name
Doxycycline
Summenformel
C22H24N2O8
Molmasse
444.43

Namen und Synonyme

DTXSID809922124-(Dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-3,4,4a,5,5a,6,12,12a-octahydrotetracene-2-carboximidic acid7164-70-7RefChem:1070088DTXCID301419281doxycycline564-25-0VibramycinDoxytetracyclineDoxycycline (anhydrous)DoxycyclinumMonodox
Weitere Namen anzeigen
doxycylineDoxycyclin hyclateDoxycyclinDOXYCYCLINE HYDRATE(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamidedoryxliviatin
DoxiciclinaDoxycycline anhydrous6alpha-Deoxy-5-oxytetracyclineVibra-tabsDoxycycline hyclate5-Hydroxy-alpha-6-deoxytetracyclineVibramycineDoxychel

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
-0,7
Polarare Oberfläche (TPSA)
182 Ų
H-Brücken-Donoren
6
H-Brücken-Akzeptoren
9
Frei drehbare Bindungen
2
Schwere Atome
32
Formalladung
0
Komplexität
956

Experimentelle und physikochemische Eigenschaften

Drugs · 3 Einträge

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Antibiotics (Tetracyclines)

Pharmaceuticals -> Listed in ZINC15

Animal Drugs · 2 Einträge

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Dissociation Constants3.09
Collision Cross Section · 4 Einträge

193.16 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

197.4 Ų [M+H]+ [CCS Type: TW]

205.7 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with Waters Major Mix]

199.24 Ų [M-H]-

Physikochemische Eigenschaften

Schmelzpunkt
206 · 206-209°C (dec.)
Siedepunkt
554.44 °C · 554.44°C (rough estimate)
Dichte
1.3809 · 1.3809 (rough estimate)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Sicherheitsdaten

Giftige Stoffe Daten
564-25-0(Hazardous Substances Data)

Chemie und Industrie

Pharmakologische Informationen

ATC CodeJ01AA02
Protein BindingWhile there is limited information available, tetracyclines bound to plasma proteins in varying degree.
Pharmacodynamics · 1 Eintrag

Doxycycline and other tetracyclines are mainly bacteriostatic and are thought to exert antimicrobial effects by the inhibition of protein synthesis. They suppress the growth of bacteria or keep them in the stationary phase of growth. Tetracyclines have antimicrobial spectrum of activity against a variety of gram-positive and gram-negative microorganisms. Cross-resistance of these microorganisms to tetracyclines is a common occurrence. As it is a highly lipophilic drug, doxycycline crosses multiple membranes of target molecules. Doxycycline shows favorable intra-cellular penetration, with bacteriostatic activity against a wide range of bacteria. Doxycycline also exhibits antiparasitic properties and anti-inflammatory actions. Its anti-inflammatory effects were investigated in various inflammatory skin conditions, such as bullous dermatoses and rosacea.

Mechanism of Action · 1 Eintrag

Protein synthesis is essential for survival and functioning of cells, including bacteria. Doxycycline inhibits bacterial protein synthesis by allosterically binding to the 30S prokaryotic ribosomal subunit. The drug blocks the association charged aminoacyl-tRNA (aa-tRNA) with the ribosomal A site, which is the acceptor site on the mRNA-ribosome complex. Doxycycline ultimately impedes the elongation phase of protein synthesis and halts the production of essential proteins for bacterial survival and functioning. Doxycycline mediates anti-inflammatory actions by preventing calcium-dependent microtubular assembly and lymphocytic proliferation, thereby inhibiting leukocyte movement during inflammation. It also inhibits nitric oxide synthase, which is an enzyme that produces nitric oxide, an inflammatory signaling molecule.

Biological Half-LifeThere is limited information available.
Metabolism/MetabolitesThere is limited information available.

Zugehörige Reaktionen

1
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1076077
HRID 1076077als Produktals Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
564-25-0、7164-70-7
PubChem CID
54671203
DTXSID
DTXSID80992212
ChEMBL
CHEMBL436921
ChEBI
CHEBI:50845
UNII
334895S862
EC Number
657-194-0
Nikkaji
J6.511K
Brechungsindex
1.65 · 1.6500 (estimate)
storage temp.
2 · under inert gas (nitrogen or Argon) at 2-8°C
Löslichkeit
125 mg/mL · DMSO : 125 mg/mL (281.26 mM; Need ultrasonic)
pka
3.5 · pKa 3.5 (Uncertain);7.7 (Uncertain);9.5 (Uncertain)
Aggregatzustand
Solid
Farbe
Light yellow to brown
Wasserlöslichkeit
0.63 g/L · 0.63g/L(25 ºC)
BCS Class
3 · 3,1
InChIKey
JBIWCJUYHHGXTC-AKNGSSGZSA-N
SMILES
C1(=O)[C@]2(O)[C@@]([H])([C@@H](O)[C@@]3([H])C(=C2O)C(=O)C2=C(C=CC=C2O)[C@@H]3C)[C@H](N(C)C)C(O)=C1C(N)=O
CAS Datenbank
564 · 564-25-0(CAS DataBase Reference)
EPA chemische Informationen
Doxycycline (564-25-0)
Absorption, Distribution and Excretion · 4 Einträge

Doxycycline is virtually completely absorbed after oral administration with a bioavailability of ranging from 73-95%. Following an oral dose of 500 mg, the Cmax of 15.3 mg/L was reached in four hours. Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 2.6 mcg/mL of doxycycline at 2 hours, decreasing to 1.45 mcg/mL at 24 hours. While a high-fat meal lowers Cmax and the rate of absorption, the effect is not clinically significant.

Tetracyclines, including doxycycline, are concentrated in bile by the liver and excreted in the urine and feces at high concentrations and in a biologically active form. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with a creatinine clearance of about 75 mL/min. This percentage may fall as low as 1-5%/72 hours in individuals with a creatinine clearance below 10 mL/min.

There is limited information available.

Population pharmacokinetic analysis of sparse concentration-time data of doxycycline following standard of care intravenous and oral dosing in 44 pediatric patients two to 18 years of age showed allometrically -scaled clearance (CL) ranging from 3.27 to 3.58 L/h/70 kg.

Verwendung und Herstellung

Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Anwendungen · 1 Eintrag

VerwendenDoxycycline is a semi-synthetic tetracycline prepared by hydrogenolysis of oxytetracycline to remove the 6-hydroxy group. Although the synthesis was reported in 1958, it was not released for use until 1967. Doxycycline, together with minocycline, is regarded as a ‘third generation’ tetracycline largely replacing the analogues and pro-drugs produced in the early 1960s for mainstream antibiotic applications. Like all tetracyclines, doxycycline shows broad spectrum antibacterial and antiprotozoan activity and acts by binding to the 30S and 50S ribosomal subunits, blocking protein synthesis. Doxycycline has been extensively cited in the literature with over 10,000 references.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

oxytetracyclinFluorwasserstoffWasserstoffMetacyclin
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: Tetracycline in which the 5beta-hydrogen is replaced by a hydroxy group, while the 6alpha-hydroxy group is replaced by hydrogen. A semi-synthetic tetracycline antibiotic, it is used to inhibit bacterial protein synthesis a d treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with chronic obstructive pulmonary disease (COPD), and adult periodontitis.